|
|
 |
|
|
|
Ind-Swift labs inaugurates its state of the Art R&D center
To focus on CRAMS and regulated markets
|
 
|
| |
| Re-inforcing its focus on Research and Development, the company has put to operation its state of the art R&D center . The new R&D Centre which is located at Mohlai, Punjab ( near to Chandigarh) has been set up at an investment of USD 5 mn.( Rs.25 crores approx.) The new R&D centre has 8 synthetic laboratories which will besides facilitating companies entry into the regulated markets with filing of 4-5 DMF’s every year, will focus on the development of NCE’s and contract research. |
| |
The new R&D center have all the latest equipments and gazettes to facilitate development of non-infringing processes, to generate data as per ICH guidelines and to prepare DMFs in CTD format for US and other regulated markets.
Company is in the process of increasing its present R&D strength of 85 to 150 scientists by 2006.
The focus of the Company behind its huge capital outlay is to facilitate ISLL's entry into regulatory markets, particularly of US & Europe, with filing of 25 DMFs by 2007-08, as drugs worth US$ 84 billion go off patent by 2008. For its nine products the Company has filed 7 DMFs in US and 50 DMFs in other European Countries. |
| |
The Company has recently put to operation three new manufacturing facilities covered under its Rs.1 bn. expansion plans. The Three facilities were a dedicated facility to manufacture Statins ( installed capacity of 40TPA) , a new dedicated facility for an Anti-Histamine drug ( installed capacity 27 TPA) and a New API facility at Samba, Jammu (installed capacity of 50TPA ) . All these facilities conforms to USFDA standards and have been put to commercial production.
The new facility at Jammu is situated in Tax free zone and shall be entitled to tax holiday for a period of ten years.
|
| |
In January last year the Company put to operation a new Low volume High value facility, strictly built as per USFDA norms. ISLL now has nine manufacturing units situated at two different locations. The production capacities of the Company has increased two-three times with these units coming into operation.
Commenting Mr. V.K.Mehta , Jt. Managing Director said that “ We have already entered into long term agreements with leading pharma companies for the supply of our products and the additional capacities are already tied up . We expect an additional revenue generation of Rs.100-120 crores from these units in the current Financial year .”
The Company expects an annual ROI of 35-40 per cent on total investment. Further the company expects the number of global companies with which it has long term tie up to double in next 2-3 years.The R&D of the company has already launched 8-10 products in the past and it plans to launch 22-25 products in next 3-4 years.
The company has already filed patent for 9 non-infringing processes and 8 more are planned in the next 2 years. These are patents for non - infringing processes of an Anti-Diabetic, Cardiovascular, Anti-Histamine & Antibiotic drug respectively.
The company is working on developing molecules under the statins, cardiology, diabetology and oncology segments. Efforts are also on for a tie-up with the originator through development of non-infringing processes and undertaking contract research for development of their molecules with an additional investment of US $ 5 million apart from the investment of US $2 million last year.
Ind-Swift Laboratories is among the few in its industry to successfully harness Chiral technology to manufacture APIs. The technology has been used in the manufacture of a number of APIs like Clopidogrel, Atorvastatin, Ezetimibe and Rosuvastatin. In addition, the company has also got the chiral synthesis of one of the compounds patented and is working to patent another such process. Besides, the R&D department has reported a breakthrough in part-reversing wastage in the use of this technology by nearly 40 per cent through recimisation, enhancing yield and profitability.
Ind-Swift laboratories limited a one of the largest manufacturers of the API and advanced intermediates in Domestic and International market has builtup large scale capacities for all the Complex molecules where it is present. Over the last few years, ISLL has shifted its focus to complex molecules and development of non - infringing processes. The company has launched and built global scale capacities in several high potential molecules like Clarithromycin, Fexofenadine and Atorvastatin – ISLL is in fact the largest producer of Clarithromycin (around 23% of global capacity) and Fexofenadine in the World after the innovators.
The company is also among the first few players to launch other complex products like Clopidogrel, Candesartan, Atorvastatin, Pioglitazone and Citalopram. The latest product launch of the Company are Nitazoxanide ( Anti –Diarroheal ) Rosuvastatin & Ezetimibe ( Anti-Hyperlipidemic), Anastrazole( Anti-cancer) and Acamprosate( Anti-alcholic) Company is first in Asia to launch Anti-Diarroheal drug “ Nitazoxanide “ after the successful clinical trials in India
ISLL is in fact the only company in the world apart from the innovator (Abbott) to have developed Clarithromycin granules, and was also the first to develop Roxithromycin granules.
Company is among the top spenders of R&D in India . The expenditure during 2004-05 was approximately 12.3% of the total turnover .
|
| |
|
To know about our Formulation Division, please visit us at Ind-Swift Limited, our other group company.
|
|
|
Copyright©2001 Ind-Swift Laboratories Limited. All rights reserved.
|
|
|
|
|
|
|
|
|
